Vancouver, Canada – Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (‘Clearmind’ or the ‘company’), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the submission of a patent application under the international Patent Cooperation Treaty (‘PCT’) as part of the company’s ongoing collaboration with the with Yissum Research Development Company of the Hebrew University of Jerusalem (‘Yissum’) pursuant to the exclusive licensing agreement that the Company entered into with Yissum.
This patent application refers to generation 3.0 of psychedelic compounds, methods of their preparation and uses thereof in the treatment of mental disorders and was developed by Prof. Dmitry Tsvelikhovsky of the Hebrew University of Jerusalem.
The PCT submission will allow the company to proceed to the national phase, which involves submitting applications to regional offices in various countries to seek patent protection in major jurisdictions like the US, Europe, China and India.
Dr. Adi Zuloff-Shani, CEO of Clearmind, commented, ‘Under the exclusive global license agreement we signed with Yissum, this patent submission, if approved, will secure the intellectual property rights of this important patent for the company. We strongly believe in the potential of psychedelic treatments to become a vital tool in treating, mental disorders and we see Clearmind, as a leading company in the space, continuing to drive innovation. We believe that this next generation psychedelic, featuring new and advanced molecules may offer an excellent therapeutic option to improve quality of life for patients suffering from mental disorders.’
Yissum is the technology transfer company of the Hebrew University of Jerusalem. Founded in 1964, Yissum serves as a bridge between cutting-edge academic research and a global community of entrepreneurs, investors, and industry. Yissum’s mission is to benefit society by converting extraordinary innovations and transformational technologies into commercial solutions that address our most urgent global challenges. The company has registered more than 11,680 patents globally, licensed over 1,160 technologies, and has spun out over 260 companies. Yissum’s business partners span the globe.
About Clearmind Medicine Inc.
Clearmind is a clinical- stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol ‘CMND’ and the Frankfurt Stock Exchange under the symbol ‘CWY0.’